Anavex Life Sciences (AVXL) Net Cash Flow (2010 - 2025)
Anavex Life Sciences (AVXL) posted Net Cash Flow of $29.2 million for Q4 2025, up 1964.54% sequentially from $1.4 million in Q3 2025, and up 355.63% YoY from $6.4 million in Q4 2024.
Anavex Life Sciences (AVXL) Net Cash Flow (2010 - 2025) Analysis & Trends
Anavex Life Sciences has reported Net Cash Flow for 16 years, with the latest figure at $29.2 million in Q4 2025.
- Quarterly Net Cash Flow rose 355.63% year-over-year to $29.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.0 million (up 147.73% YoY) and the FY2025 annual result came in at -$29.6 million, down 57.19% from the prior year.
- Net Cash Flow improved to $29.2 million in Q4 2025 per AVXL's latest filing, from $1.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $81.7 million in Q2 2021 and troughed at -$14.6 million in Q2 2025.
- A 5-year average of $4.2 million and a median of -$2.4 million in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2025: Net Cash Flow jumped 7636.27% in 2021, then tumbled 2218.57% in 2025.
- Over 5 years, Net Cash Flow stood at -$961390.0 in 2021, then sank by 475.83% to -$5.5 million in 2022, then tumbled by 31.12% to -$7.3 million in 2023, then tumbled by 57.21% to -$11.4 million in 2024, then surged by 355.63% to $29.2 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered $29.2 million, $1.4 million, and -$14.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 29.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 29.17 Mn |
| Dec 31, 2025 | 29.17 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Jun 30, 2025 | -14.61 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Mar 31, 2025 | -5.00 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Dec 31, 2024 | -11.41 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Sep 30, 2024 | -6.57 Mn |
| Jun 30, 2024 | -630,000.00 |
| Jun 30, 2024 | -630,000.00 |
| Mar 31, 2024 | -4.38 Mn |
| Mar 31, 2024 | -4.38 Mn |
| Dec 31, 2023 | -7.26 Mn |
| Dec 31, 2023 | -7.26 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Sep 30, 2023 | -3.79 Mn |